NEW BRUNSWICK, N.J., Feb. 23 /PRNewswire-FirstCall/ -- Johnson & Johnson will participate in the RBC Capital Markets' Health Care Conference on Tuesday, March 2, 2010, at the New York Palace...
Cordis to Receive $1.725 Billion BRIDGEWATER, N.J., Feb. 1 /PRNewswire/ -- Cordis Corporation, a Johnson & Johnson company, announced today that it has reached an agreement with Boston Scientific...
2009 Fourth-Quarter Sales of $16.6 Billion increased 9.0%; EPS was $0.79 2009 Full-Year Sales of $61.9 Billion decreased 2.9%; Full-Year EPS was $4.40 Excluding Special Items, 2009 Fourth-Quarter...
NEW BRUNSWICK, N.J., Jan. 19 /PRNewswire-FirstCall/ -- Johnson & Johnson will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, January 26, 2010, to discuss fourth-quarter and...
TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a...
ORLANDO, Fla., Nov. 11 /PRNewswire-FirstCall/ -- Contact lenses prescribed for longer replacement intervals can lead to more extreme over wear (stretching) that could lead to undesirable...
Telescope Prosthesis for End-Stage Macular Degeneration Highlighted SARATOGA, Calif., Oct. 20 /PRNewswire/ -- VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic...
Patients with Active Rheumatoid Arthritis Receiving SIMPONI Demonstrated Sustained Improvements in Signs and Symptoms Through One Year PHILADELPHIA, Oct. 19 /PRNewswire/ -- New long-term data...
Results from Radiographic Analyses Show Efficacy of SIMPONI in Inhibiting Joint Destruction in Two Rheumatic Conditions PHILADELPHIA, Oct. 19 /PRNewswire/ -- Phase 3 data reported for the first...
NEW BRUNSWICK, N.J., Oct. 6 /PRNewswire-FirstCall/ -- Johnson & Johnson will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, Oct. 13, 2009, to discuss third-quarter financial...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.9 | -1.35077491824 | 140.66 | 142.54 | 137.32 | 12641 | 138.80392064 | DE |
4 | -1.2 | -0.857387825093 | 139.96 | 142.54 | 136.52 | 12169 | 138.95842746 | DE |
12 | -13.06 | -8.60229218812 | 151.82 | 153.97999 | 136.52 | 9192 | 143.3492115 | DE |
26 | 3.1 | 2.28512457615 | 135.66 | 153.97999 | 135.52 | 8763 | 144.92157002 | DE |
52 | -9.14 | -6.17985125085 | 147.9 | 153.97999 | 132.74 | 9277 | 142.97919949 | DE |
156 | -14.74 | -9.60260586319 | 153.5 | 178.26 | 132.74 | 6136 | 148.2183085 | DE |
260 | 7.48 | 5.69774527727 | 131.28 | 178.26 | 104.12 | 7677 | 139.86785467 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions